• Teva Page Title

Korporativne novice

Opomba: novice so v angleškem jeziku, povezave vodijo na korporativno stran podjetja Teva.

15.02.2017

Teva Files 2016 Annual Report on Form 20-F

JERUSALEM--(BUSINESS WIRE)--Feb. 15, 2017-- In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has filed its 2016 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission. The Annual Report can be found on the company’s website at www.tevapharm.com as well as on the SEC website at www.sec.gov. In addition, security holders may request a hard copy of the Annual Report, which includes the company’s complete audited financial statements, free of charge. Requests can be made by contacting Teva ...
06.02.2017

Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman

Dr. Sol J. Barer Named Chairman of the Board JERUSALEM--(BUSINESS WIRE)--Feb. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that Dr. Yitzhak Peterburg, who has served as Chairman of the Teva Board of Directors since January 2015, has been appointed Interim President and Chief Executive Officer, effective immediately. This follows the mutual agreement between the Board of Teva and Erez Vigodman that Mr. Vigodman is stepping down. Mr. Vigodman’s service on the Teva Board of Directors has also ended. In accordance with the Israeli Companies Law, Dr. Yitzhak Peterburg has steppe...
02.02.2017

Teva Confirms Generic Victoza® Patent Challenge in the United States

JERUSALEM--(BUSINESS WIRE)--Feb. 2, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that it has filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market the generic version of Novo Nordisk's Victoza® (liraglutide) injection, in the U.S. Victoza® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Based on available information, Teva believes it is a "first applicant" to file an ANDA for the generic version of Victoza®; should its ANDA be approved, Teva...
01.02.2017

Teva to Report Fourth Quarter 2016 Financial Results on February 13, 2017

JERUSALEM--(BUSINESS WIRE)--Feb. 1, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its fourth quarter 2016 financial results on Monday, February 13, 2017 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its fourth quarter 2016 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-866-966-1396; Canada 1-866-992-6802 or Internation...
30.01.2017

Teva Confirms District Court Decision in COPAXONE® 40 mg/mL Patent Trial

JERUSALEM--(BUSINESS WIRE)--Jan. 30, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed the U.S. District Court for the District of Delaware ruling invalidating all asserted claims of the ‘250, ‘413, ‘776 and ‘302 patents for COPAXONE® (glatiramer acetate injection) 40 mg/mL. The patent infringement case involved five of six Abbreviated New Drug Application (ANDA) filers. Teva plans to appeal the decision. “We intend to move forward with an immediate appeal,” said Erez Vigodman, Teva President and CEO. “We will continue to vigorously protect our COPAXONE® franchise against further challenges ...
30.01.2017

Teva Announces FDA Approval of Two New RespiClick® Maintenance Inhalers for the Treatment of Asthma

Approvals Expand Portfolio of Respiratory Medicines Delivered in RespiClick® Inhaler Designed to Eliminate the Need for Hand-Breath Coordination During Inhalation JERUSALEM--(BUSINESS WIRE)--Jan. 30, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) approved two products for adolescent and adult patients with asthma. These products, AirDuoTM RespiClick® (fluticasone propionate and salmeterol inhalation powder) and ArmonAirTM RespiClick® (fluticasone propionate inhalation powder), include medication delivered via Teva’s RespiClick® breath-a...
18.01.2017

Teva Receives FDA Approval for VANTRELATM ER (Hydrocodone Bitartrate) Extended-Release Tablets [CII] Formulated with Proprietary Abuse Deterrence Technology

VANTRELA ER label describes the product’s abuse-deterrent properties against abuse in the three most common routes—oral, intranasal and intravenous JERUSALEM--(BUSINESS WIRE)--Jan. 18, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) approved VANTRELATM ER (hydrocodone bitartrate) extended-release tablets [CII] formulated with Teva’s proprietary abuse deterrence technology. VANTRELA ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options...
09.01.2017

Teva Announces Completion of Sale of UK and Ireland Actavis Assets and Operations Following European Commission Approval

JERUSALEM--(BUSINESS WIRE)--Jan. 9, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the completion of the sale of the majority of the assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited (a subsidiary of Intas Pharmaceuticals Ltd). The sale, first announced in October last year, has completed for an agreed value of GBP 603 million following approval from the European Commission. The divestment of specified Actavis Generics assets and operations in the UK and Ireland was part of an undertaking that Teva made to the European Commission in order to obta...
06.01.2017

Teva to Present at the 35th Annual J.P. Morgan Healthcare Conference

JERUSALEM--(BUSINESS WIRE)--Jan. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the 35th Annual J.P. Morgan Healthcare Conference. Teva’s management will present on Monday, January 9, 2017 at 9:30 AM PST. What:   Teva Presentation at the 35th Annual J.P. Morgan Healthcare Conference   When: ...